Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gracell Reports Positive Data from Trial of Off-the Shelf CAR-T Candidate

publication date: Apr 12, 2021

Gracell Biotech, a Suzhou cell therapy company, reported positive results from a China Phase I trial of its allogeneic CAR-T candidate. GC027 targets CD7. It was administered to adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) who had previously been treated with a median of six therapies. A single infusion of GC027 at one of three dosing levels produced a complete remission in all six patients. In the future, Gracell plans to test GC027 in global markets for T-All and other cancers as well. More details...

Stock Symbol: (NDQQ: GRCL)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here